76153-06-5Relevant articles and documents
TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
-
Page/Page column 55; 57-58, (2013/11/05)
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as m PGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS
-
Page/Page column 109, (2013/07/25)
The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol as defined in the specification, or a salt thereof.
Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile
Velaparthi, Upender,Liu, Peiying,Balasubramanian, Balu,Carboni, Joan,Attar, Ricardo,Gottardis, Marco,Li, Aixin,Greer, Ann,Zoeckler, Mary,Wittman, Mark D.,Vyas, Dolatrai
, p. 3072 - 3076 (2008/02/07)
A series of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) were examined in which the pendant imidazole moiety was replaced to improve selectivity for IGF-1R inhibition over cytochrome P450 (CYP). Synthesis and SAR of these compounds is presented.